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Background: Studies in patients with peripheral arterial disease (PAD) have reported an association between inflammatory
markers and severity of disease or worsening of symptoms. However, few have studied the prognostic significance of
inflammatory markers in asymptomatic subjects, measured many years before the onset of symptomatic PAD requiring
treatment (trPAD).
Material and methods: Five inflammation-sensitive plasma proteins (ISPs), including fibrinogen, 1-antitrypsin, hapto-
globin, ceruloplasmin, and orosomucoid, were determined in 5619 healthy men (mean age, 46.8  3.7 years) without
walking-induced calf pain. Data for men who subsequently underwent a revascularization procedure because of trPAD
(intermittent claudication or critical ischemia) were retrieved from hospital-based registers. Future trPAD was studied in
relation to the number of ISPs in the top quartile at the baseline examination.
Results: Seventy men (1.2%) underwent revascularization because of trPAD at a mean of 16.5 years after the baseline
examination. The proportion with future trPAD was 0.4%, 1.0%, 1.5%, and 3.2%, respectively, for men with 0, 1, 2, and
3 or more ISPs in the top quartile (trend, P < .0001). After adjustment for age, screening year, systolic blood pressure,
blood pressure medication, cholesterol concentration, diabetes, smoking, and tobacco consumption the corresponding
odds ratios (95% confidence interval [CI]) were 1.00 (reference), 1.5 (CI, 0.7-3.6), 1.9 (CI, 0.8-4.6), and 2.9 (CI,
1.3-6.4), respectively, in these groups (trend, P  .003).
Conclusion: Elevated ISPs, measured 16 years earlier in apparently healthy men without walking-induced calf pain, were
associated with increased risk for development of PAD requiring revascularization. (J Vasc Surg 2004;40:1101-5.)
Clinical Relevance: Elevated levels of inflammation-sensitive plasma proteins are risk factors for development of
peripheral arterial disease in need of revascularization. The proteins are elevated already in men without walking-induced
calf-pain many years before the vascular intervention. The results suggest that measurements of inflammation-sensitive
plasma proteins can be useful in a global risk factor assessment, to identify patients who need intensified risk factor
management.Peripheral arterial disease (PAD) includes a wide range
of atherosclerotic manifestations in the lower limbs, from
asymptomatic atherosclerosis to symptomatic disease rang-
ing from intermittent claudication to critical limb ischemia,
with ulcers, rest pain, or gangrene. Severe symptoms that
require revascularization or amputation will develop in a
minority of patients with symptomatic PAD; the annual risk
has been estimated at approximately 1% to 2%.1-6
The relationship between elevated levels of inflammation-
sensitive proteins (ISPs) and increased incidenceofmyocardial
infarction (MI), stroke, and cardiovascular death is well estab-
lished.7-11 Not so many have studied the association of ISPs
with the incidence of PAD. Studies of patients with PADhave
reported associations between hemostatic or inflammatory
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doi:10.1016/j.jvs.2004.09.017markers and severity of disease or worsening of symp-
toms.12-18 Recent studies have reported an increased inci-
dence of PAD,mostly self-reported intermittent claudication,
in men with elevated levels of C-reactive protein or fibrino-
gen.19,20 However, few have studied the relation between
elevated ISPs, measured in subjects with asymptomatic dis-
ease, and risk for future development of PAD.
Previous studies from the Malmö Preventive Study
have shown that the incidence of MI,9 stroke,21 and ab-
dominal aortic aneurysm22 is increased in apparently
healthy men with elevated levels of ISPs (fibrinogen, oro-
somucoid, 1-antitrypsin, haptoglobin, ceruloplasmin).
The present study in middle-aged men from the general
population, initially without walking-induced calf pain, was
carried out to assess the relation between ISPs and future
onset of PAD requiring revascularization (trPAD).
METHODS
Between 1974 and 1984, 22,444 men participated in a
screening program for detection of high risk for cardiovas-
cular diseases.23 Complete birth cohorts from the city of
Malmö, Sweden, were invited by letter. The participation
rate was 71%. Determination of the 5 plasma proteins was
part of the program in 6193 men, ages 28 to 61 years,
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and 1982. After exclusion of men with a history of MI,
stroke, or cancer, according to questionnaire and the Swed-
ish MI register, 6075 men remained. Another 456 men
who reported walking-induced calf pain at the baseline
screening were also excluded, and their data were separately
analyzed and presented.24 Of these, trPAD developed in 17
(3.7%). The health service authority of Malmö approved
and funded the screening program. All participants gave
informed consent.
Baseline examinations. The examinations took place
in the morning, with subjects in smoke-free and fasting
condition. Subjects were categorized as smokers or non-
smokers. Smokers were subdivided into 3 groups: fewer
than 10 cigarettes per day, 10 to 19 cigarettes per day, and
20 or more cigarettes per day.
Blood pressure was measured twice in the right arm
after a 10-minute rest, and the average of the 2 measure-
ments was used. A sphygmomanometer and a rubber cuff
of appropriate size were used. Use of anti-hypertensive
medication was assessed with a questionnaire.
Blood samples were taken after an overnight fast, and
analyzed at the Department of Clinical Chemistry at
Malmö University Hospital. Serum cholesterol concentra-
tions were analyzed with standard methods at the hospital
laboratory. For glucose analysis a routine hexokinase
method was used. Diabetes was considered present in men
with fasting whole blood glucose concentration greater
than 6.1 mmol/L or 2-hour glucose concentration greater
than 10.0 mmol/L, and men who reported that they had
diabetes.25
Physical activity was assessed with a questionnaire. Men
who reported that they were mostly sedentary in their spare
time were considered physically inactive.
Body mass index was calculated as weight divided by
height squared (kg/m2).
ISPs. Electroimmunoassay was used to analyze the
plasma levels of 5 ISPs.26 The analysis was performed
consecutively at the time of screening, and was based on 1
blood draw. The precision of the analysis had a variation of
less than 5%.26 The detection limits were 20 mg/L for
ceruloplasmin, 50 mg/L for 1-antitrypsin, and 350mg/L
for orosomucoid, haptoglobin, and fibrinogen. We have
previously reported that the correlation coefficients be-
tween the individual proteins range between 0.31 and 0.56
and that cardiovascular risk increases with the number of
ISPs in the top quartile.9,21,22 In accord with previous
studies, the sample was therefore categorized according to
the number of elevated ISPs. The top quartiles in the study
population were as follows: fibrinogen, greater than
4.0 g/L; orosomucoid, greater than 0.93 g/L; 1-anti-
trypsin, greater than 1.42 g/L; haptoglobin, greater than
1.76 g/L; and ceruloplasmin, greater than 0.36 g/L.9
Patients. Patient data were retrieved from the local
Swedish Vascular registry,27 which systematically has regis-
tered all patients who have undergone open vascular or
endovascular reconstruction procedures since 1987. Pa-
tients who underwent revascularization because of inter-mittent claudication or critical ischemia between 1987 and
2002 at Malmö University Hospital or Lund University
Hospital were included in the registry. The population base
of these hospitals is approximately 735,000, and includes
the population of Malmö and surrounding cities and areas.
The case-retrieval procedures for incidence of MI and
stroke have been reported elsewhere.9
Statistical analysis. One-way analysis of variance and
the Pearson 2 test were used to compare risk factors
among patients and control subjects. Logistic regression
analysis was performed to investigate the relationships be-
tween ISPs and trPAD, with adjustment for potential con-
founders. The Kaplan-Meier method with log-rank statis-
tics was used to compare incidence rates in men with and
without trPAD during follow-up.
RESULTS
Patients. A total of 70 men underwent revasculariza-
tion because of trPAD. The indications were critical isch-
emia (n  32) and intermittent claudication (n  38).
Mean time from baseline examination to revascularization
was 16.5  4.3 years (range, 7.8-24.8 years). Age at
revascularization was 63.9  6.1 years (range, 46.1-77.5
years).
Eleven of the 64 smokers had quit smoking at revascu-
larization. Diabetes developed in 9 men during follow-up.
Thirteen patients (12.3 per 1000 person-years) had
nonfatal MI, and 6 men (5.3 per 1000) had stroke during
the period from the screening examination to vascular
reconstruction. In men without trPAD during follow-up
(n  5549), incidence of nonfatal MI was 3.7 per 1000
person-years, incidence of fatal MI was 1.8 per 1000, and
incidence of stroke was 2.0 per 1000. Incidence of nonfatal
MI (P  .0001) and stroke (P  .003) were significantly
higher in men with trPAD.
Baseline characteristics in men with trPAD and in
control subjects. Systolic blood pressure was higher in
patients compared with control subjects (P  .001), and
prevalence of smoking (P .001) and diabetes (P .001)
was higher. There were no significant differences in body
mass index, level of physical activity, or age at baseline
(Table I). Cholesterol concentration was slightly higher in
patients compared with control subjects (6.0  0.9 vs 5.7
1.0 mmol/L; P  .03). Men in whom trPAD later
developed had higher levels of all ISPs (Table I).
Incidence of trPAD in relation to ISP levels. The
percentage with trPAD during follow-up was 0.4%, 1.0%,
1.5%, and 3.2%, respectively, in men with 0, 1, 2, and 3 or
more ISPs in the top quartile (trend, P  .001). The
relation between trPAD and number of elevated ISPs was
observed for both trPAD with indication of critical isch-
emia (0.2%, 0.5%, 0.6%, 1.4%, respectively, for men with 0,
1, 2, and 3 and more elevated ISPs) and intermittent
claudication (0.2%, 0.6%, 1.0%, 1.7%, respectively).
The relation between number of elevated ISPs and risk
for trPAD remained significant after adjustment for poten-
tial confounders (Table II).
0.95
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trPAD) and nonsmokers (n  2975; 6 trPAD), and pres-
ence of diabetes (n  296; 15 trPAD) and absence of
diabetes (n  5323; 55 trPAD). Even though trPAD
developed in few nonsmokers and men with diabetes, the
relationship between ISPs and risk for trPAD was largely
the same in all groups (Table III).
Incidence of trPAD in relation to individual ISPs.
For all individual ISPs, incidence of trPAD was highest in
the top quartile of the protein. Before adjustments, all
trends were significant. After adjustments for confounders,
only 1-antitrypsin and orosomucoid showed significant
relationships (Table IV).
DISCUSSION
In men from the general population, who initially were
without walking-induced calf-pain, the number of elevated
ISPs was associated with incidence of trPAD. ISPs were
significantly elevated many years (mean, 16.5 years) before
Table I. Baseline characteristics in men with and without
N
Age (y)
Smokers (%)
20 cigarettes/day (% of smokers)
Diabetes (%)
Systolic blood pressure (mm Hg)
Diastolic blood pressure (mm Hg)
Blood pressure medication (%)
Cholesterol (mmol/L)
Body mass index (kg/m2)
Physical inactivity (%)
Inflammation-sensitive plasma proteins (g/L)
1-antitrypsin
Ceruloplasmin
Fibrinogen
Haptoglobin
Orosomucoid
Table II. Surgical lower limb revascularization procedures
proteins at baseline in 5619 men initially without walking-
Inflammation
0 1
All men (n) 2291 144
Men with revascularization
during follow-up
9 (0.4%) 15 (1.
Claudication 4 8
Critical ischemia 5 7
Revascularization adjusted
OR* (95% CI)
1.00 1.5 (0.7
P values represent P for trend.
*Odds ratio adjusted for age, screening year, systolic blood pressure, blood
consumption.any surgical or endovascular intervention. This relationremained significant after adjustmens for potential con-
founders, including age, smoking, blood pressure, choles-
terol concentration, and diabetes.
The ISPs used in our analysis are central elements in the
acute and chronic inflammatory response.28,29 The pro-
teins have been used for many years in clinical practice, to
assess the degree of inflammation and to differentiate be-
tween inflammatory diseases. The method for their analysis
is well accepted and accurate.26 However, the measure-
ments were limited to the analyses that were available in
routine practice at the time of screening. For example, we
had no information about high sensitive-C-reactive protein
or different lipoproteins.
It is now widely accepted that elevated ISPs are associ-
ated with increased incidence of cardiovascular diseases.
The causes for this relationship remain unclear. Develop-
ment of atherosclerosis involves different stages, including
initiation of the lesion, progression of the lesion, and
plaque complications.30 The relative contribution of in-
ical lower limb revascularization during follow-up
Revascularization
Pes No
0 5549
4.0 46.8  3.7 .21
1 46 .001
9 23 .003
.4 5.1 .001
19 129  16 .001
11 87  10 .10
3 4.2 .001
0.9 5.7  1.0 .03
3.6 24.9  3.3 .25
6 56 .99
0.23 1.27  0.27 .001
0.07 0.32  0.07 .001
0.83 3.50  0.80 .001
0.94 1.37  0.67 .001
0.25 0.81  0.20 .001
ing follow-up in relation to inflammation-sensitive plasma
ced calf pain
itive plasma proteins in top quartile
P2 3
840 1047
13 (1.5%) 33 (3.2%) .0001
8 18
5 15
) 1.9 (0.8-4.6) 2.9 (1.3-6.4) .003
ure medication, cholesterol concentration, diabetes, smoking, and tobaccosurg
Y
7
47.4
9
3
21
137
89
1
6.0
24.5 
5
1.40 
0.35
3.89
1.84dur
indu
-sens
1
0%)
-3.6
pressflammation in these stages is unclear, and the role of
f subj
dicatio
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atherosclerotic process.31 In addition to development of
atherosclerosis, the final stages of PAD also include critical
ischemia and gangrene. In this study the ISPs were similarly
associated with risk for development of critical ischemia and
intermittent claudication. Even though fibrinogen has an
important role in thrombogenesis and is a determinant of
blood viscosity, we could not find any support for the
hypothesis that these proteins are differentially related to
critical ischemia and intermittent claudication.
Of the individual ISPs, only 1-antitrypsin and oroso-
mucoid remained significantly associated with trPAD after
adjustment for potential confounders. However, the num-
ber of elevated ISPs showed stronger associations with
incidence of trPAD than did any of the individual ISPs. This
measure also had acceptable reliability in terms of internal
consistency; that is, the correlation between each protein
and the remaining sum score was fully adequate (Cronbach
  0.65 in this cohort). The present results and several
previous studies9,21,22 suggest that a combination of sev-
eral inflammatorymarkers is more informative than individ-
ual markers in studies of cardiovascular diseases and cardio-
vascular risk factors.
Elevated ISPs are also strongly associated with inci-
dence ofMI, stroke, and all-cause mortality.9,21,22 It can be
assumed that many men with PAD and high ISPs died
before the vascular disease required surgical treatment.
Table III. Surgical lower limb revascularization during fo
sensitive plasma proteins in categories of smoking and diab
Inflammation-s
0 1
n % n
trPAD in smokers 7 1.0 14
trPAD in nonsmokers 2 0.1 1
trPAD with diabetes 2 2.1 3
trPAD without diabetes 7 0.3 12
P values represent P for trend.
Values represent number of trPAD (%) of all men in each group.
trPAD, Peripheral arterial disease requiring revascularization.
*No P value was computed for nonsmokers, because of the small number o
Table IV. Proportion with revascularization during follow
Quart
1 2
1-Antitrypsin (%) 0.5 0.8
Ceruloplasmin (%) 0.7 0.8
Fibrinogen (%) 0.6 0.8
Haptoglobin (%) 0.5 1.1
Orosomucoid (%) 0.6 0.5
P values represent P for trend.
*Adjusted for age, screening year, systolic blood pressure, blood pressure me
in a logistic regression model.Because of the phenomenon of “competing causes ofdeaths,” this probably reduced the association between
elevated ISPs and trPAD. This assumption is also supported
in that incidence of nonfatal MI was much higher in men in
whom trPAD developed.
One question is whether atherosclerosis could cause
elevated ISPs, that is, whether elevated ISPs merely reflect
the extension and severity of preexisting atherosclerosis.
The degree of preexisting atherosclerosis is unknown. Men
with walking-induced calf pain were excluded from the
analysis. Even though this should be adequate for the
purpose of excluding subjects with symptomatic intermit-
tent claudication, it is likely that many men had very early,
asymptomatic stages of disease. However, previous studies
that compared patients with stable and unstable angina
pectoris with healthy control subjects suggest that athero-
sclerosis per se has small effects on the inflammation.32 The
long period between the baseline examination and the PAD
intervention also supports the view that severe atheroscle-
rosis was not the main reason for the elevated ISP levels.
This population-based study sought to explore the
relations between inflammatory markers and the risk for
development of trPAD. No attempt was made to study
patients who had received medical treatment or had symp-
toms of low severity. This is both a strength and a weakness
of the present study. The accuracy of the diagnosis and the
severity of disease are unquestionable in those who under-
went surgical intervention for trPAD. Inasmuch as few
up in relation to number of elevated inflammation-
ve plasma proteins in top quartile
P
2 3 or more
n % n %
13 2.6 30 3.9 .001
0 0 3 1.1 *
5 10.9 5 6.8 .07
8 1.0 28 2.9 .001
ects.
in quartiles of 5 inflammation-sensitive plasma proteins
P P*3 4
1.3 2.3 .001 .02
1.6 2.1 .001 .09
1.2 2.4 .001 .11
0.8 2.6 .001 .14
1.7 2.2 .001 .049
n, cholesterol concentration, diabetes, smoking, and tobacco consumption,llow-
etes
ensiti
%
2.0
0.1
3.7
0.9-up
ilepopulation-based studies have investigated this group, it is
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mately develops. On the other hand, we cannot make any
conclusions about the risk for development of PAD with-
out need of revascularization.
The local Swedish Vascular registry was used for case
retrieval. Because the Swedish Vascular registry was started
in 1987, cases from the first years of follow-up could not be
included. Mean age of this rather young cohort was 46.8
years. Because PAD is strongly related to age, it is likely that
few patients underwent revascularization during the first
years. It is possible that some cases were lost because the
subjects moved out from the area. However, there is no
reason to assume that this was related to the ISPs. We do
not know whether some patients, for some reason, were
more likely to be scheduled for a revascularization proce-
dure and whether this could be related to ISP levels at
baseline. Even though access to health care is equal and free
of charge in Sweden, we cannot completely exclude this
possibility. It is also possible that some patients who re-
quired amputation were lost. However, in almost all cases
surgical reconstruction procedures were performed before
amputation, and these were included in the registry. Inas-
much as many other cardiovascular end points, such as
incidence of MI, stroke, death, hypertension, and abdom-
inal aortic aneurysm, have shown similar relations with the
ISPs in this cohort, it seems unlikely that biased case finding
explains the present results.
Elevated ISP levels were associated with increased risk
for trPAD. The risk increased progressively with the num-
ber of elevated ISPs. In this prospective study of men who
initially were without walking-induced calf pain, ISPs were
already elevated 16 years before reconstruction was needed.
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